Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
28.75
-0.64 (-2.18%)
At close: Aug 26, 2026, 4:00 PM EDT
28.50
-0.25 (-0.87%)
Pre-market: Aug 27, 2026, 5:35 AM EDT
Immunome Revenue
In the year 2025, Immunome had annual revenue of $6.94M, down -23.23%.
Revenue (ttm)
$6.94M
Revenue Growth
-23.23%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
247
Market Cap
3.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.94M | -2.10M | -23.23% |
| Dec 31, 2024 | 9.04M | -4.98M | -35.50% |
| Dec 31, 2023 | 14.02M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tarsus Pharmaceuticals | 606.33M |
| Arcutis Biotherapeutics | 463.98M |
| AbCellera Biologics | 66.17M |
| uniQure | 18.67M |
| Alumis | 7.40M |
| NewAmsterdam Pharma Company | 7.12M |
| Celldex Therapeutics | 158.00K |
IMNM News
- 10 days ago - Immunome price target raised to $35 from $31 at Wedbush - TheFly
- 15 days ago - Immunome reports Q2 EPS (65c), consensus (50c) - TheFly
- 15 days ago - Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 15 days ago - Immunome Earnings release: Q2 2026 - Filings
- 15 days ago - Immunome Quarterly report: Q2 2026 - Filings
- 20 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Immunome announces first patient dosed in Phase 1 IM-3050 trial - TheFly
- 5 weeks ago - Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors - Business Wire